Lincoln Pharmaceuticals Limited Stock Price Today (NSE: LINCOLN)
Fundamental Score
Lincoln Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Lincoln Pharmaceuticals Limited share price today is ₹590.70, down 1.97% on NSE/BSE as of 16 September 2026. Lincoln Pharmaceuticals Limited (LINCOLN) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.18K (Cr). The 52-week high for LINCOLN share price is ₹770.00 and the 52-week low is ₹440.00. At a P/E ratio of 12.27x, LINCOLN is currently trading below its industry average P/E of 34.89x. 0
Lincoln Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Lincoln Pharmaceuticals Limited share price chart: 6.69% return over the past month. 52-week high ₹770.00, 52-week low ₹440.00.
Lincoln Pharmaceuticals Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹606.65 | ₹609.95 | ₹586.10 | ₹590.70 | 33.11K (Cr) | |
| ₹625.05 | ₹630.90 | ₹600.00 | ₹602.60 | 62.53K (Cr) | |
| ₹635.00 | ₹635.00 | ₹619.10 | ₹623.50 | 34.33K (Cr) | |
| ₹641.60 | ₹647.05 | ₹631.00 | ₹634.40 | 27.78K (Cr) | |
| ₹639.90 | ₹642.90 | ₹632.35 | ₹637.50 | 31.33K (Cr) | |
| ₹637.35 | ₹648.40 | ₹633.45 | ₹639.80 | 1.11L (Cr) | |
| ₹626.80 | ₹640.00 | ₹617.70 | ₹632.35 | 75.01K (Cr) | |
| ₹627.00 | ₹631.00 | ₹618.00 | ₹620.80 | 29.09K (Cr) | |
| ₹627.35 | ₹627.35 | ₹619.00 | ₹622.65 | 22.96K (Cr) | |
| ₹611.30 | ₹629.45 | ₹605.40 | ₹618.35 | 56.38K (Cr) |
Lincoln Pharmaceuticals Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹613.00 | ₹648.40 | ₹586.10 | ₹590.70 | -3.64% | |
| ₹578.90 | ₹646.95 | ₹572.00 | ₹606.75 | +4.81% | |
| ₹633.20 | ₹635.95 | ₹569.70 | ₹577.15 | -8.85% | |
| ₹632.95 | ₹659.45 | ₹585.10 | ₹623.50 | -1.49% | |
| ₹647.00 | ₹770.00 | ₹620.00 | ₹632.95 | -2.17% | |
| ₹575.00 | ₹733.00 | ₹545.00 | ₹645.80 | +12.31% | |
| ₹605.50 | ₹651.45 | ₹560.40 | ₹564.95 | -6.70% | |
| ₹458.75 | ₹677.00 | ₹452.90 | ₹631.05 | +37.56% | |
| ₹485.20 | ₹505.00 | ₹440.00 | ₹456.45 | -5.93% | |
| ₹510.00 | ₹515.00 | ₹464.40 | ₹483.95 | -5.11% | |
| ₹530.50 | ₹542.90 | ₹490.00 | ₹511.95 | -3.50% | |
| ₹531.00 | ₹545.00 | ₹518.00 | ₹529.80 | -0.23% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Lincoln Pharmaceuticals Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Lincoln Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LINCOLN across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Excellent ROCE Performance (15.87%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (19.69%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 12.27 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (15.07%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (115.14x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 4.71)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹233.89 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Below-Average Return on Equity (0.00%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Limited Institutional Interest (FII+DII: 4.87%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Lincoln Pharmaceuticals Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Lincoln Pharmaceuticals Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Lincoln Pharmaceuticals LimitedLincoln Pharmac...Selected✓ LINCOLN • 531633 | 53.3/100 | ₹590.70₹591 | ₹1183.15₹1183.15 | 12.27Average 12.3 Average | 0.00%Poor 0.00% Poor | 15.87%Good 15.87% Good | 0.01Excellent 0.0 Excellent | 7.11%Good 7.11% Good | 10.19%Good 10.19% Good | 0.30% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1861.00₹1861 | ₹446509.73₹446509.73 | 36.92Average 36.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9438.50₹9439 | ₹250120.25₹250120.25 | 85.64Average 85.6 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1117.80₹1118 | ₹111556.44₹111556.44 | 24.91Average 24.9 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1373.30₹1373 | ₹110942.04₹110942.04 | 32.90Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1945.00₹1945 | ₹105078.63₹105078.63 | 96.00Average 96.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1668.40₹1668 | ₹95999.74₹95999.74 | 26.07Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1143.00₹1143 | ₹95440.50₹95440.50 | 29.54Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2077.80₹2078 | ₹95007.40₹95007.40 | 17.17Average 17.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2238.40₹2238 | ₹92445.92₹92445.92 | 45.23Average 45.2 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price446509.73 Cr
- Divi's Laboratories Limited share price250120.25 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price111556.44 Cr
- Cipla Limited share price110942.04 Cr
Lincoln Pharmaceuticals Limited PE Ratio History
Historical price-to-earnings ratio for LINCOLN — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹41.11 | ₹483.95 | 11.8x |
| FY 2024 | ₹46.58 | ₹787.80 | 16.9x |
| FY 2023 | ₹36.40 | ₹609.50 | 16.7x |
| FY 2022 | ₹34.63 | ₹355.55 | 10.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Lincoln Pharmaceuticals Limited Dividend History
Annual cash dividends paid by LINCOLN — dividend yield 0.30%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹3.61 Cr |
| FY 2024 | ₹3.00 Cr |
| FY 2023 | ₹3.00 Cr |
| FY 2022 | ₹3.00 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Lincoln Pharmaceuticals Limited Quarterly Performance
Latest quarterly metrics for LINCOLN — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
15.07%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
0.43%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.19%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
7.11%
Compounded annual net profit growth over 5 years
Lincoln Pharmaceuticals Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for LINCOLN — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Lincoln Pharmaceuticals Limited Financial Statements
Annual income statement, balance sheet and cash flow for Lincoln Pharmaceuticals Limited (LINCOLN) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Lincoln Pharmaceuticals Limited
About LINCOLN (Lincoln Pharmaceuticals Limited)
Lincoln Pharmaceuticals Ltd is a dynamic and forward-thinking pharmaceutical company dedicated to enhancing global health through the development, manufacturing, and distribution o...f high-quality medicines. With a strong focus on innovation and patient well-being, Lincoln Pharmaceuticals strives to address diverse medical needs across a wide spectrum of therapeutic areas. The company's state-of-the-art manufacturing facilities adhere to stringent international quality standards, ensuring the safety and efficacy of its products. Committed to research and development, Lincoln Pharmaceuticals continuously explores new formulations and drug delivery systems to improve treatment outcomes and patient compliance. The company's ethical business practices, coupled with its dedication to social responsibility, solidify its position as a trusted healthcare partner. Lincoln Pharmaceuticals' comprehensive product portfolio encompasses a diverse range of therapeutic categories, catering to various medical conditions and patient populations. From essential medicines addressing common ailments to specialized treatments for chronic diseases, the company's offerings are designed to improve the quality of life for individuals worldwide. A dedicated team of medical professionals and scientists work collaboratively to develop and refine formulations, ensuring optimal therapeutic benefits. By leveraging cutting-edge technology and adhering to rigorous quality control measures, Lincoln Pharmaceuticals consistently delivers safe, effective, and affordable medicines to meet the evolving healthcare needs of the global community. Beyond its domestic operations, Lincoln Pharmaceuticals has established a robust international presence, exporting its products to numerous countries across diverse continents. This global reach reflects the company's commitment to making quality healthcare accessible to people around the world. By forging strategic partnerships and navigating complex regulatory landscapes, Lincoln Pharmaceuticals continues to expand its market presence and contribute to the advancement of healthcare in emerging and developed economies alike. The company's unwavering dedication to quality, innovation, and patient-centricity positions it as a reliable and trusted provider of pharmaceutical solutions on a global scale.
Company Details
Key Leadership
LINCOLN Share Price: Frequently Asked Questions
What is the current share price of Lincoln Pharmaceuticals Limited?
Lincoln Pharmaceuticals Limited (LINCOLN) trades at ₹590.70 on NSE and BSE. Market cap ₹1.18K (Cr). Educational data only.
What is the P/E ratio of Lincoln Pharmaceuticals Limited?
Lincoln Pharmaceuticals Limited has a P/E of 12.27x vs industry average 34.89x.
What is the Bull Run score for Lincoln Pharmaceuticals Limited?
Lincoln Pharmaceuticals Limited has a Bull Run score of 53.3/100 based on 25+ financial parameters.
Does Lincoln Pharmaceuticals Limited pay dividends?
Lincoln Pharmaceuticals Limited has a dividend yield of 0.30%. Past dividends don't guarantee future payments.
What is the ROE of Lincoln Pharmaceuticals Limited?
Lincoln Pharmaceuticals Limited has ROE of 0.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Lincoln Pharmaceuticals Limited?
Lincoln Pharmaceuticals Limited has debt-to-equity of 0.01.
Is Lincoln Pharmaceuticals Limited a good investment?
Bull Run gives Lincoln Pharmaceuticals Limited a score of 53.3/100. This is not investment advice — consult a SEBI-registered advisor.